• The FDA grants PRVs to companies that are developing products that address rare pediatric diseases, rare infectious diseases, or biodefense threats. The PRV entitles its holder to receive a priority review of their NDA or BLA.
  • KYBORA developed a comprehensive list of companies that would be interested in acquiring a PRV, performed a valuation analysis to understand the likely value of a PRV at that particular time, used its connections at the highest level of pharma organizations to engage in transaction discussions, quickly obtaining an offer that was in the range of what PRVs sold for. Bayer asked that we obtain two more offers to confirm the range of valuation. KYBORA was able to quickly meet this demand. KYBORA used the results of that outreach to negotiate an improved value for the deal.
  • The agreement demonstrates KYBORA’s ability to quickly find buyers for PRVs and deliver superior results for its clients.
  • To learn more about our this transaction, please click here.

About the author.


20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

No Comments. Leave a comment  

Leave a Reply

Your email address will not be published. Required fields are marked *